NCT02599714View on ClinicalTrials.gov

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

March 30, 2018

Study Completion Date

November 23, 2023

Conditions
Advanced and Metastatic Breast Cancer
Interventions
DRUG

AZD2014

The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.

DRUG

Palbociclib

cyclin dependent kinase inhibitor

DRUG

Fulvestrant

Fulvestrant hormonal therapy as background

Trial Locations (7)

34232

Research Site, Sarasota

37203

Research Site, Nashville

48201

Research Site, Detroit

53226

Research Site, Milwaukee

92024

Research Site, Encinitas

L7 8XP

Research Site, Liverpool

W1G 6AD

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY